Intraperitoneal tenoxicam to prevent abdominal adhesion formation in a rat peritonitis model.
OBJECTIVE
We investigated the effects of intraperitoneal tenoxicam on the development of postoperative intra-abdominal adhesions and oxidative stress in a model of bacterial peritonitis.


METHODS
Bacterial peritonitis was induced in 24 rats by cecal ligation and puncture. The rats were randomly assigned to one of three groups. Group 1 (n = 8) received 2 ml saline intraperitoneally, group 2 (n = 8) received 2 ml (0.5 mg/kg) tenoxicam (Oksamen) intraperitoneally, and group 3 (n = 8) was a control, which did not receive any injection. All animals were killed 14 days later so we could assess the adhesion score and measure anastomotic bursting pressures. Tissue antioxidant levels were measured in 1-g tissue samples taken from the abdominal wall.


RESULTS
The adhesion score was significantly lower in the tenoxicam group than in the saline and control groups. The anastomotic bursting pressures were higher in the saline and tenoxicam groups than in the control group. The catalase (CAT) levels were higher in the saline and tenoxicam groups than in the control group. The malondialdehyde (MDH) levels were higher in the saline group than in the tenoxicam and control groups.


CONCLUSIONS
Intraperitoneal tenoxicam inhibited the formation of postoperative intra-abdominal adhesions without compromising wound healing in this bacterial peritonitis rat model. Tenoxicam also decreased the oxidative stress during peritonitis.
Ezberci
Fikret
F
Department of Surgery, University of Kahramanmaras, Genel Cerrahi ABD, Turkey.
Bulbuloglu
Ertan
E
Ciragil
Pinar
P
Gul
Mustafa
M
Kurutas
Ergul Belge
EB
Bozkurt
Serdar
S
Kale
I Taner
IT
D000005:Abdomen; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D007274:Injections, Intraperitoneal; D023421:Models, Animal; D018384:Oxidative Stress / Q000187:drug effects; D010538:Peritonitis / Q000382:microbiology / Q000503:physiopathology*; D010894:Piroxicam / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011184:Postoperative Period; D051381:Rats; D017208:Rats, Wistar; D000267:Tissue Adhesions / Q000517:prevention & control*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; C032801:tenoxicam